Subscribe to RSS
DOI: 10.1055/s-0043-1769582
A Study on Enumeration of Factors Prone to the Development of COVID-19-Associated Mucormycosis
Author's Financial Disclosures None.
Abstract
Background Patients with pre-existing chronic medical conditions with altered immunity are prone to COVID-19-associated mucormycosis (CAM).
Objective In this study, our objectives were to identify the risk factors that increase the chances of developing CAM and to determine the severity of the risk factors of CAM. Thereby, we can optimize the modifiable risk factors for developing CAM in coronavirus disease 2019 (COVID-19) patients. For instance, better control of blood glucose levels in COVID-19 patients can decrease the risk of developing CAM.
Materials and Methods The data was collected retrospectively from 1000 COVID-19 infected patients, above the age of 18 years during the time period of March 2021 to August 2021, in which 86 patients had confirmed CAM.
Statistical Analysis Binary logistic regression and curve estimation analysis were performed using SPSS software version 29 for identifying the associated risk factors of CAM with the significance of p-value less than 0.05.
Results Factors such as severe inflammation (p = 0.048), high dose of steroid administration (p = 0.005), increasing age (p < 0.001), and prolonged hospital stay (p < 0.001) were statistically proven to be significant risk factors, associated with CAM.
Conclusion Increasing age, severe inflammation, high dose of steroid administration, and prolonged hospital stay have association with occurrence of CAM.
Ethics
The study obtained the human ethics permission from the Institutional Human Ethical Committee. The approval date and number are August 16, 2022 and IHEC # 208, respectively. Due to the retrospective study design, waiver of the informed consent was obtained.
Declaration
The study was performed in accordance with Declaration of Helsinki.
Publication History
Article published online:
19 June 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Garg S, Masheshwari D, Bhushan B, Sardana V, Jain RK. Covid-19 and mucormycosis superinfection: prospective, observational study in a single center. Ann Indian Acad Neurol 2022; 25 (03) 441-448
- 2 Mishra Y, Prashar M, Sharma D, Akash, Kumar VP, Tilak TVSVGK. Diabetes, COVID 19 and mucormycosis: clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr 2021; 15 (04) 102196
- 3 Chandley P, Subba P, Rohatgi S. COVID-19-associated mucormycosis: a matter of concern amid the SARS-CoV-2 pandemic. Vaccines (Basel) 2022; 10 (08) 1266
- 4 Sahu RK, Salem-Bekhit MM, Bhattacharjee B. et al. Mucormycosis in Indian COVID-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies. Antibiotics (Basel) 2021; 10 (09) 1079
- 5 Dogra S, Arora A, Aggarwal A. et al. Mucormycosis amid COVID-19 crisis: pathogenesis, diagnosis, and novel treatment strategies to combat the spread. Front Microbiol 2022; 12: 794176
- 6 Tavakolpour S, Irani S, Yekaninejad MS. et al. Risk factors of COVID-19 associated mucormycosis (CAM) in Iranian patients: a single-center retrospective study. Mycopathologia 2022; 187 (5-6): 469-479
- 7 Al-Tawfiq JA, Alhumaid S, Alshukairi AN. et al. COVID-19 and mucormycosis superinfection: the perfect storm. Infection 2021; 49 (05) 833-853
- 8 Zirpe K, Pote P, Deshmukh A, Gurav SK, Tiwari AM, Suryawanshi P. A retrospective analysis of risk factors of COVID-19 associated mucormycosis and mortality predictors: a single-center study. Cureus 2021; 13 (10) e18718
- 9 Bala K, Chander J, Handa U, Punia RS, Attri AK. A prospective study of mucormycosis in north India: experience from a tertiary care hospital. Med Mycol 2015; 53 (03) 248-257
- 10 Rudrabhatla PK, Reghukumar A, Thomas SV. Mucormycosis in COVID-19 patients: predisposing factors, prevention and management. Acta Neurol Belg 2022; 122 (02) 273-280
- 11 Sen M, Honavar SG, Bansal R. et al; members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021; 69 (07) 1670-1692
- 12 Bhanuprasad K, Manesh A, Devasagayam E. et al. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int J Infect Dis 2021; 111: 267-270
- 13 Selarka L, Sharma S, Saini D. et al. Mucormycosis and COVID-19: An epidemic within a pandemic in India. Mycoses 2021; 64 (10) 1253-1260
- 14 Gupta S, Ahuja P. Risk factors for procurrence of mucormycosis and its manifestations post Covid-19: a single arm retrospective unicentric clinical study. Indian J Otolaryngol Head Neck Surg 2022; 74 (Suppl. 02) 3131-3138
- 15 Patel A, Kaur H, Xess I. et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020; 26 (07) 944.e9-944.e15